close

Agreements

Date: 2012-06-19

Type of information: R&D agreement

Compound: new medicines for the treatment of diabetes and related metabolic disorders

Company: Sanofi (France) Joslin Diabetes Center (USA)

Therapeutic area: Metabolic diseases

Type agreement:

R&D

Action mechanism:

Disease: diabetes and related metabolic disorders

Details:

Sanofi  and the Joslin Diabetes Center, a teaching and research affiliate of Harvard Medical School, will collaborate to promote the development of new medicines for the treatment of diabetes and related disorders. The collaboration was unveiled at the 2012 Bio International Convention in Boston, Mass. Building on Joslin’s experience in diabetes research and care, the collaboration will focus on four key areas within diabetes and related metabolic disorders to identify potential new biologics or small drug candidates for the treatment of late complications of diabetes and new insulin analogs with more targeted efficacy.Additionally, research will address the challenges of insulin resistance and personalized medicine, with the overall aim of improving the lives of people living with diabetes.
Under the terms of the agreement, Sanofi has options to commercialize the results of the research. Both parties will have access to intellectual property for internal research use.

Financial terms:

Financial details of the collaboration were not disclosed.

Latest news:

Is general: Yes